A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment - a study of the CESAR central european society for anticancer drug research - EWIV**

1Tumor Biology Center at the Albert-Ludwigs-University Freiburg, 2Magnetic Resonance Development & Application Center (MRDAC) of the University Freiburg, Freiburg, 3Institute of Pharmacy, Clinical Pharmacy, University Bonn, Bonn, 4Innere Klinik (Tumorforschung), West German Cancer Center, Universitatsklinikum Essen, Essen, 5Department Hematology and Oncology, University Hospital Herne, University Bochum, Bochum, Germany, 6CESAR Central European Society for Anticancer Drug Research-EWIV, Vienna, Austria, and 7Department of Gastroenterology, University Hospital Freiburg, Germany